Connective Tissue Diseases



Article No.

No. of tests

EliA Symphony Well 14-5508-01 4x12 tests
EliA CTD Screen 14-5596-01 4x12 tests


Promotion material

Performance folder
EliA ANA Differentiation
Sm, U1RNP, RNP70, RO, La, Scl-70, CENP, Jo-1


Antinuclear antibodies bind intracellular antigens and are serological hallmarks of systemic rheumatic diseases. In contrast to indirect immunofluorescence assays, ELISAs do not screen the whole range of antinuclear antibodies but only those known to be specific for connective tissue diseases.

Antigens in the EliA Symphony:

U1-snRNP (human recombinant U1 70 kD, A and C)
Sm (purified from human HeLa cells)
SS-A/Ro (human recombinant 52 kD and 60 kD)

(human recombinant)

Scl-70 (human recombinant topoisomerase 1)
CENP (human recombinant CENP-B)
Jo-1 (human recombinant histidyl tRNA synthetase)


Antigens in the EliA CTD Screen:

U1RNP (human recombinant (RNP70, A, C))
SS-A/Ro (human recombinant (60 kDa, 52 kDa))


(human recombinant)
centromere B

(human recombinant)

Scl-70 (human recombinant)
Jo-1 (human recombinant)
fibrillarin (human recombinant)
RNA Pol III (human recombinant)
Rib-P (human recombinant)
PM-Scl (human recombinant)
PCNA (human recombinant)
Mi-2 proteins (human recombinant)
Sm proteins (human recombinant)
DNA (native purified)


Disease association, antibody prevalence and specificity


Disease and Prevalence

Clinical Significance


SLE: 60-90% Specific marker in SLE, dsDNA antibodies correlate with disease activity (monitoring), marker for tissue damage, dsDNA antibodies are associated with an increased risk of nephritis, specificity is 95%.
(70 kDa, A, C)
SLE: 30-70%
MCTD: 100%
U1 snRNP antibodies indicate a good prognosis concerning the development of renal involvement, also when they are found in combination with Sm.
MCTD is defined through high levels of anti-U1 snRNP.
(B, B', D)
SLE: 10-30% Specific marker for SLE (specificity 99%)
(52 kD, 60 kD)
SLE: 25-50%
SS: 60-90%
Neonatal lupus: >95%
High risk of neonatal lupus if mother has SS-A/Ro (especially when directed to 52 kD) and SS-B/La antibodies
SS-B/La SLE: 5-15%
SS: 40-95%
Neonatal lupus
SS-B/La antibodies are found almost always in combination with anti-SSA antibodies; more specific than Anti-SS-A/Ro for Sjögren's syndrome
Scl-70 Scleroderma:
Specific marker for scleroderma (specificity 98-100%)
CREST: 50% (other sources: 40-90%)
Raynaud's disease: 10-15%
Present in patients with limited form of scleroderma
Jo-1 Poly-/dermatomyositis: 30% Patients often have lung involvement. Jo-1 antibodies-positive patients tend to have a severe disease with poor response to therapy.

Disease activity

Single antigens in the profile have a good correlation with the disease activity, others do not. For monitoring, the measurement of single specificities is recommended.

When is the measurement recommended?

Suspicion of connective tissue disease.

Antibody isotypes



J.B. Peter, Y. Shoenfeld (1996)  |  Venrooij WJ, Maini RN (1996)  |  Peene I, Meheus L, Veys EM, De Keyser F (2001)  |  Peng SL, Hardin JA, Craft J (1997)

Back to top